Preventing RSV Infection in Children: Current Passive Immunizations and Vaccine Development

Overview

Journal Pathogens

Date 2025 Feb 26

PMID 40005481

Authors

Pius I Babawale

Ivan Martinez-Espinoza

Alaine M Mitchell

Antonieta Guerrero-Plata

Affiliations

Soon will be listed here.

Abstract

Human respiratory syncytial virus (RSV) is a leading cause of acute respiratory tract infection and lower respiratory tract infection, associated with high morbidity and mortality in young children, the elderly, and immunocompromised individuals. Initial attempts to develop an RSV vaccine in the 1960s were faced with a setback due to the enhanced RSV disease developed by vaccinated children. More recent advancements have led to the generation of RSV vaccines for older adults and pregnant women. However, there are still no commercially available RSV vaccines for infants. This work summarizes the current passive immunizations and the ongoing efforts to develop an RSV vaccine for infants.

References

Langley J, Nolan T, Ramet M, Richmond P, Rosario Filho N, Haazen W . A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12-24 Months. Open Forum Infect Dis. 2024; 11(9):ofae453. PMC: 11365064. DOI: 10.1093/ofid/ofae453. View

Boyoglu-Barnum S, Chirkova T, Anderson L . Biology of Infection and Disease Pathogenesis to Guide RSV Vaccine Development. Front Immunol. 2019; 10:1675. PMC: 6677153. DOI: 10.3389/fimmu.2019.01675. View

Karron R, Luongo C, Mateo J, Wanionek K, Collins P, Buchholz U . Safety and Immunogenicity of the Respiratory Syncytial Virus Vaccine RSV/ΔNS2/Δ1313/I1314L in RSV-Seronegative Children. J Infect Dis. 2019; 222(1):82-91. PMC: 7199783. DOI: 10.1093/infdis/jiz408. View

Abbasi H, Oduoye M . Revitalizing hope for older adults: The use of the novel Arexvy for immunization against respiratory syncytial virus. Health Sci Rep. 2023; 6(10):e1648. PMC: 10617982. DOI: 10.1002/hsr2.1648. View

Topalidou X, Kalergis A, Papazisis G . Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines. Pathogens. 2023; 12(10). PMC: 10609699. DOI: 10.3390/pathogens12101259. View

Stobart C, Rostad C, Ke Z, Dillard R, Hampton C, Strauss J . A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation. Nat Commun. 2016; 7:13916. PMC: 5187593. DOI: 10.1038/ncomms13916. View

McLellan J, Yang Y, Graham B, Kwong P . Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011; 85(15):7788-96. PMC: 3147929. DOI: 10.1128/JVI.00555-11. View

Widagdo W, Bastian A, Jastorff A, Scheys I, De Paepe E, Comeaux C . Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and High-Dose Influenza Vaccine in Adults 65 Years and Older: A Noninferiority Trial. J Infect Dis. 2023; 230(2):e374-e383. PMC: 11326816. DOI: 10.1093/infdis/jiad594. View

Grimaldi M, Gouyon B, Sagot P, Quantin C, Huet F, Gouyon J . Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia. Pediatr Pulmonol. 2007; 42(3):189-92. DOI: 10.1002/ppul.20503. View

10.

Polack F, Alvarez-Paggi D, Libster R, Caballero M, Blair R, Hijano D . Fatal enhanced respiratory syncytial virus disease in toddlers. Sci Transl Med. 2021; 13(616):eabj7843. PMC: 10712289. DOI: 10.1126/scitranslmed.abj7843. View

11.

Bartsch Y, Cizmeci D, Yuan D, Mehta N, Tolboom J, De Paepe E . Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine. J Virol. 2023; 97(11):e0077123. PMC: 10688327. DOI: 10.1128/jvi.00771-23. View

12.

Jorgensen S . Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants. J Antimicrob Chemother. 2023; 78(5):1143-1149. DOI: 10.1093/jac/dkad076. View

13.

Ginsburg A, Srikantiah P . Respiratory syncytial virus: promising progress against a leading cause of pneumonia. Lancet Glob Health. 2021; 9(12):e1644-e1645. PMC: 8585487. DOI: 10.1016/S2214-109X(21)00455-1. View

14.

Wilson E, Goswami J, Baqui A, Doreski P, Perez-Marc G, Zaman K . Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. N Engl J Med. 2023; 389(24):2233-2244. DOI: 10.1056/NEJMoa2307079. View

15.

Alamares-Sapuay J, Kishko M, Lai C, Parrington M, Delagrave S, Herbert R . Mutations in the F protein of the live-attenuated respiratory syncytial virus vaccine candidate ΔNS2/Δ1313/I1314L increase the stability of infectivity and content of prefusion F protein. PLoS One. 2024; 19(4):e0301773. PMC: 11003679. DOI: 10.1371/journal.pone.0301773. View

16.

Garegnani L, Styrmisdottir L, Roson Rodriguez P, Escobar Liquitay C, Esteban I, Franco J . Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev. 2021; 11:CD013757. PMC: 8594174. DOI: 10.1002/14651858.CD013757.pub2. View

17.

Fly J, Eiland L, Stultz J . Nirsevimab: Expansion of Respiratory Syncytial Virus Prevention Options in Neonates, Infants, and At-Risk Young Children. Ann Pharmacother. 2024; 59(1):81-91. DOI: 10.1177/10600280241243357. View

18.

Ha E, Kim J, Han B, Shin J, Lee E, Lee K . Viral respiratory infections requiring hospitalization in early childhood related to subsequent asthma onset and exacerbation risks. J Med Virol. 2024; 96(9):e29876. DOI: 10.1002/jmv.29876. View

19.

Li Y, Wang X, Blau D, Caballero M, Feikin D, Gill C . Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022; 399(10340):2047-2064. PMC: 7613574. DOI: 10.1016/S0140-6736(22)00478-0. View

20.

Johnson S, Oliver C, Prince G, Hemming V, Pfarr D, Wang S . Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997; 176(5):1215-24. DOI: 10.1086/514115. View